JP2012509259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509259A5 JP2012509259A5 JP2011536365A JP2011536365A JP2012509259A5 JP 2012509259 A5 JP2012509259 A5 JP 2012509259A5 JP 2011536365 A JP2011536365 A JP 2011536365A JP 2011536365 A JP2011536365 A JP 2011536365A JP 2012509259 A5 JP2012509259 A5 JP 2012509259A5
- Authority
- JP
- Japan
- Prior art keywords
- hsa linker
- seq
- composition
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 64
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 29
- 229960000575 trastuzumab Drugs 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 229960002949 fluorouracil Drugs 0.000 claims description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- 229960003668 docetaxel Drugs 0.000 claims description 5
- 229960003881 letrozole Drugs 0.000 claims description 5
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- 229940123237 Taxane Drugs 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 4
- PAEZRCINULFAGO-OAQYLSRUSA-N (R)-homocamptothecin Chemical compound CC[C@@]1(O)CC(=O)OCC(C2=O)=C1C=C1N2CC2=CC3=CC=CC=C3N=C21 PAEZRCINULFAGO-OAQYLSRUSA-N 0.000 claims description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- OPQNCARIZFLNLF-UHFFFAOYSA-N ansamitocin P-3 Natural products CN1C(=O)CC(OC(=O)C(C)C)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 OPQNCARIZFLNLF-UHFFFAOYSA-N 0.000 claims description 3
- OPQNCARIZFLNLF-JBHFWYGFSA-N ansamitocin P3 Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)C(C)C)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 OPQNCARIZFLNLF-JBHFWYGFSA-N 0.000 claims description 3
- 108010044540 auristatin Proteins 0.000 claims description 3
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- 229940127093 camptothecin Drugs 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- 190000008236 carboplatin Chemical compound 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960001338 colchicine Drugs 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960002087 pertuzumab Drugs 0.000 claims description 3
- 229960004622 raloxifene Drugs 0.000 claims description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 2
- 241000699660 Mus musculus Species 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004891 lapatinib Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 238000011580 nude mouse model Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 201000000292 clear cell sarcoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11579708P | 2008-11-18 | 2008-11-18 | |
| US61/115,797 | 2008-11-18 | ||
| USPCT/US2009/040259 | 2009-04-10 | ||
| PCT/US2009/040259 WO2009126920A2 (en) | 2008-04-11 | 2009-04-10 | Human serum albumin linkers and conjugates thereof |
| PCT/US2009/060721 WO2010059315A1 (en) | 2008-11-18 | 2009-10-14 | Human serum albumin linkers and conjugates thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509259A JP2012509259A (ja) | 2012-04-19 |
| JP2012509259A5 true JP2012509259A5 (OSRAM) | 2013-05-23 |
| JP5677972B2 JP5677972B2 (ja) | 2015-02-25 |
Family
ID=42198443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536365A Expired - Fee Related JP5677972B2 (ja) | 2008-11-18 | 2009-10-14 | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US8927694B2 (OSRAM) |
| JP (1) | JP5677972B2 (OSRAM) |
| KR (1) | KR20110112301A (OSRAM) |
| CN (1) | CN102282168A (OSRAM) |
| BR (1) | BRPI0921586A2 (OSRAM) |
| WO (1) | WO2010059315A1 (OSRAM) |
Families Citing this family (157)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
| US8580263B2 (en) * | 2006-11-21 | 2013-11-12 | The Regents Of The University Of California | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
| PT2129396E (pt) | 2007-02-16 | 2013-11-18 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| WO2009036379A2 (en) | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| WO2010059315A1 (en) * | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| MX2012002014A (es) | 2009-08-17 | 2012-06-13 | Roche Glycart Ag | Inmunoconjugados dirigidos. |
| KR101874834B1 (ko) | 2009-10-30 | 2018-07-05 | 알부메딕스 에이/에스 | 알부민 변이체 |
| CN104610454A (zh) * | 2010-02-16 | 2015-05-13 | 米迪缪尼有限公司 | Hsa相关组合物及使用方法 |
| AU2011224186C1 (en) | 2010-03-11 | 2015-04-02 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| KR20130070576A (ko) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
| WO2011139681A1 (en) | 2010-04-26 | 2011-11-10 | Merrimack Pharmaceuticals | Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug |
| EA201291181A1 (ru) | 2010-05-06 | 2013-05-30 | Новартис Аг | Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) |
| AU2011249783B9 (en) | 2010-05-06 | 2014-11-06 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (LRP6) antibodies |
| AU2011255238B2 (en) | 2010-05-21 | 2015-06-04 | Silver Creek Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| KR102447595B1 (ko) | 2010-11-30 | 2022-09-26 | 추가이 세이야쿠 가부시키가이샤 | 세포상해 유도 치료제 |
| KR20140041396A (ko) | 2010-12-06 | 2014-04-04 | 메리맥 파마슈티컬즈, 인크. | 안트라사이클린 화학요법제를 포함하는 erbb2-표적 면역리포좀으로의 치료에서 심장독성을 예방하기 위한 용량 및 투여 |
| WO2012091563A1 (en) * | 2010-12-27 | 2012-07-05 | Apo-T B.V. | A polypeptide that binds aberrant cells and induces apoptosis |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| CN103547598A (zh) * | 2011-02-24 | 2014-01-29 | 梅里麦克制药股份有限公司 | 包含抗-erbb3药剂的联合治疗 |
| CN103732628B (zh) | 2011-03-03 | 2017-06-23 | 酵活有限公司 | 多价杂多聚体骨架设计和构建体 |
| US20140134170A1 (en) * | 2011-03-11 | 2014-05-15 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
| CN103429262A (zh) * | 2011-03-15 | 2013-12-04 | 梅里麦克制药股份有限公司 | 克服对erbb途径抑制剂的抗性 |
| BR112013028536A2 (pt) | 2011-05-05 | 2016-11-29 | Novozymes Biopharma Dk As | variantes de albumina |
| EP2760892A1 (en) | 2011-09-29 | 2014-08-06 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| ES2666856T3 (es) * | 2011-11-04 | 2018-05-08 | Novartis Ag | Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media |
| WO2013075066A2 (en) | 2011-11-18 | 2013-05-23 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| WO2013096939A1 (en) * | 2011-12-23 | 2013-06-27 | Sri International | Selective binding compounds |
| WO2013096940A1 (en) * | 2011-12-23 | 2013-06-27 | Sri International | Double binding constructs |
| SG11201404007WA (en) | 2012-01-13 | 2014-08-28 | Apo T B V | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
| US20150011736A1 (en) * | 2012-01-20 | 2015-01-08 | Sea Lane Biotechnologies, Llc | Binding molecule conjugates |
| PL2825556T3 (pl) | 2012-03-16 | 2018-10-31 | Albumedix A/S | Warianty albuminy |
| US20150139936A1 (en) * | 2012-05-11 | 2015-05-21 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| US9499634B2 (en) | 2012-06-25 | 2016-11-22 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| CN104768571B (zh) | 2012-07-13 | 2018-11-09 | 酵活有限公司 | 多价异多聚体支架设计和构建体 |
| US9345766B2 (en) | 2012-08-30 | 2016-05-24 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-ERBB3 agents |
| CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| WO2014089127A1 (en) | 2012-12-03 | 2014-06-12 | Merrimack Pharmaceuticals, Inc. | Combination therapy for treating her2-positive cancers |
| WO2014098464A1 (ko) * | 2012-12-18 | 2014-06-26 | 이화여자대학교 산학협력단 | 인간혈청알부민 열안정화용 조성물 및 이를 이용한 열안정화된 인간혈청알부민의 제조방법 |
| WO2014121033A1 (en) * | 2013-02-04 | 2014-08-07 | Fl Therapeutics Llc | Soluble complexes of drug analogs and albumin |
| US9943568B2 (en) | 2013-04-18 | 2018-04-17 | Armo Biosciences, Inc. | Methods of using pegylated interleukin-10 for treating cancer |
| AU2014262566A1 (en) | 2013-05-08 | 2015-11-12 | Zymeworks Inc. | Bispecific HER2 and HER3 antigen binding constructs |
| EA032164B1 (ru) * | 2013-05-13 | 2019-04-30 | Вижн Глобал Холдингс Лтд. | Содержащая модифицированное лекарственное вещество на основе гемоглобина фармацевтическая композиция для таргетной терапии рака и диагностической визуализации |
| WO2014186905A1 (en) * | 2013-05-24 | 2014-11-27 | Zymeworks Inc. | Modular protein drug conjugate therapeutic |
| WO2014204816A2 (en) | 2013-06-17 | 2014-12-24 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| EP3038642A4 (en) | 2013-08-30 | 2017-01-18 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| EP3052129A2 (en) | 2013-09-30 | 2016-08-10 | Daiichi Sankyo Company, Limited | Protein biomarker and uses thereof |
| EP3068425B1 (en) | 2013-11-11 | 2021-01-27 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| KR102237803B1 (ko) | 2013-12-25 | 2021-04-09 | 다이이찌 산쿄 가부시키가이샤 | 항 trop2 항체-약물 컨쥬게이트 |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| WO2015109012A1 (en) * | 2014-01-14 | 2015-07-23 | Integrated Biotherapeutics, Inc. | Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins |
| HUE044389T2 (hu) | 2014-01-31 | 2019-10-28 | Daiichi Sankyo Co Ltd | Anti-HER2 antitest-hatóanyag konjugátum |
| US11279770B2 (en) * | 2014-02-28 | 2022-03-22 | Merus N.V. | Antibody that binds ErbB-2 and ErbB-3 |
| CA3244411A1 (en) | 2014-02-28 | 2025-11-29 | Merus N.V. | Antibodies that bind egfr and erbb3 |
| WO2015156268A1 (ja) | 2014-04-07 | 2015-10-15 | 中外製薬株式会社 | 免疫活性化抗原結合分子 |
| ES2754348T3 (es) | 2014-04-10 | 2020-04-17 | Daiichi Sankyo Co Ltd | Conjugado de (anticuerpo anti-HER2)-fármaco |
| US11473080B2 (en) * | 2014-04-30 | 2022-10-18 | The Board Of Trustees Of The University Of Illinois | Method for generating high affinity, bivalent binding agents for sandwich assays |
| CA2947157A1 (en) | 2014-05-13 | 2015-11-19 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| BR112016025056A2 (pt) | 2014-05-14 | 2018-02-20 | F. Hoffmann-La Roche Ag | uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica |
| WO2015200837A1 (en) | 2014-06-27 | 2015-12-30 | Fl Therapeutics Llc | Abiraterone derivatives and non-covalent complexes with albumin |
| US20160045596A1 (en) | 2014-08-05 | 2016-02-18 | Merrimack Pharmaceuticals, Inc. | Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies |
| GB201417067D0 (en) * | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
| CA2970927A1 (en) * | 2014-10-31 | 2016-05-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tlr9 targeted cytotoxic agents |
| MX391279B (es) | 2015-01-08 | 2025-03-21 | Genmab As | Anticuerpos biespecíficos contra cd3 y cd20. |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| KR20180020141A (ko) | 2015-05-28 | 2018-02-27 | 아르모 바이오사이언시스 인코포레이티드 | 암 치료에 사용되는 peg화된 인터류킨-10 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| US11359015B2 (en) | 2015-07-15 | 2022-06-14 | Genmab A/S | Humanized or chimeric CD3 antibodies |
| CN108135881B (zh) * | 2015-08-11 | 2020-11-13 | 同宜医药（苏州）有限公司 | 多配体药物偶联体及其用途 |
| CN108137674B (zh) | 2015-08-20 | 2022-12-06 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体和缀合物 |
| SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| KR102714060B1 (ko) | 2015-08-21 | 2024-10-08 | 입센 바이오팜 리미티드 | 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법 |
| AU2016312510A1 (en) | 2015-08-25 | 2018-03-08 | Armo Biosciences, Inc. | Methods of using Interleukin-10 for treating diseases and disorders |
| JP6933379B2 (ja) * | 2015-09-24 | 2021-09-08 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 転移を低減するための方法および組成物 |
| EP3355907B1 (en) | 2015-10-02 | 2021-01-20 | Silver Creek Pharmaceuticals, Inc. | Bi-specific therapeutic proteins for tissue repair |
| WO2017066726A1 (en) | 2015-10-16 | 2017-04-20 | Merrimack Pharmaceuticals, Inc. | Stabilizing camptothecin pharmaceutical compositions |
| BR112018008068A2 (en) | 2015-10-23 | 2018-11-13 | Merus N.V. | binding molecules that inhibit cancer growth |
| JP6925278B2 (ja) | 2015-11-18 | 2021-08-25 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
| WO2017086367A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| KR101746152B1 (ko) | 2015-12-07 | 2017-06-13 | 주식회사 이수앱지스 | ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도 |
| JP7146637B2 (ja) | 2015-12-22 | 2022-10-04 | アルブミディクス リミティド | 改善されたタンパク質発現株 |
| WO2017112847A1 (en) | 2015-12-22 | 2017-06-29 | Albumedix A/S | Improved protein expression strains |
| WO2017161173A1 (en) | 2016-03-16 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Engineered trail for cancer therapy |
| EP3484922A1 (en) | 2016-07-14 | 2019-05-22 | Genmab A/S | Multispecific antibodies against cd40 and cd137 |
| AU2017354903B2 (en) | 2016-11-02 | 2023-04-13 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| CN110337590A (zh) | 2016-11-04 | 2019-10-15 | 奥胡斯大学 | 以新生儿Fc受体过表达为特征的肿瘤的识别和治疗 |
| CA3046293A1 (en) | 2016-12-12 | 2018-06-21 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| MX2019008059A (es) | 2017-01-17 | 2019-12-11 | Daiichi Sankyo Co Ltd | Anticuerpo anti-gpr20 y conjugado de anticuerpo-medicamento anti-gpr20. |
| AU2018231618B2 (en) | 2017-03-09 | 2025-02-13 | Genmab A/S | Antibodies against PD-L1 |
| EA201992063A1 (ru) | 2017-03-31 | 2020-03-26 | Мерус Н.В. | СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1 |
| TW202530220A (zh) | 2017-05-15 | 2025-08-01 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| JP7296891B2 (ja) | 2017-05-17 | 2023-06-23 | メルス ナムローゼ フェンノートシャップ | 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ |
| JP7282693B2 (ja) | 2017-06-20 | 2023-05-29 | アルブミディクス リミティド | 改良されたタンパク質発現株 |
| AU2018309339C1 (en) | 2017-08-04 | 2025-08-21 | BioNTech SE | Binding agents binding to PD-L1 and CD137 and use thereof |
| PT3665198T (pt) | 2017-08-09 | 2025-05-02 | Merus Nv | Anticorpos que ligam egfr e cmet |
| JP7366745B2 (ja) | 2017-08-31 | 2023-10-23 | 第一三共株式会社 | 抗体－薬物コンジュゲートの改良製造方法 |
| KR20250047840A (ko) | 2017-08-31 | 2025-04-04 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 신규 제조 방법 |
| US11548931B2 (en) | 2017-11-16 | 2023-01-10 | Xl-Protein Gmbh | PASylated VEGFR/PDGFR fusion proteins and their use in therapy |
| AU2019270459B2 (en) | 2018-05-18 | 2025-08-28 | Daiichi Sankyo Co., Ltd. | Anti-MUC1 antibody-drug conjugate |
| US12358999B2 (en) | 2018-07-27 | 2025-07-15 | Daiichi Sankyo Company, Limited | Protein recognizing drug moiety of antibody-drug conjugate |
| US12220604B2 (en) | 2018-07-31 | 2025-02-11 | Daiichi Sankyo Company, Limited | Treatment of metastatic brain tumor by administration of an antibody-drug conjugate |
| US12077586B2 (en) | 2018-09-19 | 2024-09-03 | LAVA Therapeutics N.V. | Bispecific antibodies for use in the treatment of hematological malignancies |
| US20210369842A1 (en) | 2018-11-06 | 2021-12-02 | Genmab A/S | Antibody formulation |
| CN109627337B (zh) * | 2018-12-29 | 2023-07-21 | 上海复宏汉霖生物技术股份有限公司 | 一种抗prlr的单克隆抗体及其制备方法和应用 |
| KR20210141466A (ko) | 2019-02-01 | 2021-11-23 | 라바 테라퓨틱스 비.브이. | 새로운 cd40 결합 항체 |
| NL2022494B1 (en) | 2019-02-01 | 2020-08-19 | Lava Therapeutics B V | Novel CD40-binding antibodies |
| CN111603567B (zh) * | 2019-02-22 | 2024-12-27 | 赣江新区博瑞创新医药有限公司 | Cd44靶向多臂偶联物 |
| CN113710229B (zh) | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| WO2020197943A1 (en) * | 2019-03-26 | 2020-10-01 | Shimadzu Corporation | Photoimmunotherapy and pharmaceutical agent used therefor |
| US20230399376A1 (en) * | 2019-05-27 | 2023-12-14 | Baker Heart and Diabetes Institute | Binding proteins comprising the extracellular domain of cd39 and methods of treating or preventing neurological diseases |
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| WO2021111143A1 (en) | 2019-12-04 | 2021-06-10 | Albumedix Limited | Methods and compositions produced thereby |
| WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
| PT3865155T (pt) * | 2020-02-13 | 2023-01-02 | Orano Med | Processo para modificação específica de local de um anticorpo |
| IL296362A (en) | 2020-03-18 | 2022-11-01 | Genmab As | Antibodies that bind to b7h4 |
| US20230293647A1 (en) | 2020-04-09 | 2023-09-21 | Autolus Limited | Polypeptide |
| IL297986A (en) | 2020-05-08 | 2023-01-01 | Genmab As | Bispecific antibodies against cd3 and cd20 |
| GB202007441D0 (en) | 2020-05-19 | 2020-07-01 | Autolus Ltd | Polypeptide |
| JP2023532807A (ja) | 2020-07-08 | 2023-07-31 | ラヴァ・セラピューティクス・エヌ・ヴイ | Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体 |
| KR20230065256A (ko) | 2020-08-06 | 2023-05-11 | 비온테크 에스이 | 코로나바이러스 s 단백질용 결합제 |
| MX2023002545A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes. |
| MX2023002546A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpos biespecificos contra cumulo de diferenciacion 3 (cd3) y contra cumulo de diferenciacion 20 (cd20) para tratar leucemia linfocitica cronica. |
| US20240016944A1 (en) * | 2020-11-10 | 2024-01-18 | New York University | Macropinocytosis selective monobody-drug conjugates |
| CN116888153A (zh) | 2020-12-10 | 2023-10-13 | 熔岩疗法公司 | 与γ-δT细胞受体结合的抗体 |
| CA3202218A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| KR20230169950A (ko) | 2021-02-26 | 2023-12-18 | 라바 테라퓨틱스 엔.브이. | Cd123 및 감마-델타 t 세포 수용체에 결합하는 항체 |
| WO2022234146A1 (en) | 2021-05-07 | 2022-11-10 | Genmab A/S | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3 |
| IL309319A (en) | 2021-06-21 | 2024-02-01 | Genmab As | Combined dosage regimen CD137 and PD-L1 binding agents |
| EP4363439A4 (en) * | 2021-06-30 | 2025-12-17 | Silver Creek Pharmaceuticals Inc | Chimeric proteins for the targeted release of growth factors to the glomerulus |
| WO2023037333A1 (en) | 2021-09-13 | 2023-03-16 | Janssen Biotech, Inc | CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER |
| CA3234153A1 (en) | 2021-10-08 | 2023-04-13 | David Satijn | Antibodies binding to cd30 and cd3 |
| WO2023067138A1 (en) | 2021-10-21 | 2023-04-27 | LAVA Therapeutics N.V. | Uses of gamma delta t cell activating antibodies |
| JP2024546948A (ja) * | 2021-12-15 | 2024-12-26 | ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド | コンジュゲート、それらの組成物、及びそれらの関連する方法 |
| WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
| EP4285926A1 (en) | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
| EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| NL2032398B1 (en) | 2022-07-06 | 2024-01-23 | Academisch Ziekenhuis Leiden | Bispecific antibody and uses thereof |
| EP4438624A1 (en) | 2023-03-27 | 2024-10-02 | LAVA Therapeutics N.V. | Antibodies that bind nectin-4 and gamma-delta t cell receptors |
| WO2024200573A1 (en) | 2023-03-27 | 2024-10-03 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| EP4442251A1 (en) | 2023-04-05 | 2024-10-09 | Albumedix Ltd | Formulations and uses thereof |
| WO2024208898A1 (en) | 2023-04-05 | 2024-10-10 | Genmab A/S | Pharmaceutical compositions comprising antibodies binding to cd30 and cd3 |
| TW202509077A (zh) | 2023-06-30 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 與纖維母細胞活化蛋白α及死亡受體４結合之抗體 |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| WO2025024780A1 (en) | 2023-07-27 | 2025-01-30 | LAVA Therapeutics N.V. | Antibodies that bind gamma-delta t cell receptors for the treatment of cancer |
| CN120361243A (zh) * | 2023-08-18 | 2025-07-25 | 上海美雅珂生物技术有限责任公司 | 5t4抗体药物偶联物及其应用 |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| WO2025158071A1 (en) | 2024-01-26 | 2025-07-31 | Sartorius Albumedix Limited | Retroviral preparations containing albumin for enhancing transduction efficiency, uses thereof for cell transduction |
Family Cites Families (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6009A (en) * | 1849-01-09 | Improvement in machines for gathering pea-vines | ||
| US5800815A (en) | 1903-05-05 | 1998-09-01 | Cytel Corporation | Antibodies to P-selectin and their uses |
| US4450103A (en) | 1982-03-01 | 1984-05-22 | Cetus Corporation | Process for recovering human IFN-β from a transformed microorganism |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5753627A (en) | 1988-12-05 | 1998-05-19 | Novartis Ag | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5705363A (en) | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
| US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
| WO1992015682A1 (en) | 1991-02-27 | 1992-09-17 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US6027725A (en) | 1991-11-25 | 2000-02-22 | Enzon, Inc. | Multivalent antigen-binding proteins |
| DK0617706T3 (da) | 1991-11-25 | 2001-11-12 | Enzon Inc | Multivalente antigenbindende proteiner |
| FR2686620B1 (fr) | 1992-01-27 | 1995-06-23 | Rhone Poulenc Rorer Sa | Serum-albumine humaine, preparation et utilisation. |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| NZ261259A (en) | 1993-01-12 | 1996-12-20 | Biogen Inc | Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments |
| CN1074243A (zh) | 1993-02-06 | 1993-07-14 | 北京中化生物技术研究所 | 白介素6-白介素2融合蛋白及其制法和用途 |
| US5780594A (en) | 1993-03-01 | 1998-07-14 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Biologically active protein fragments containing specific binding regions of serum albumin or related proteins |
| US5914110A (en) | 1993-09-07 | 1999-06-22 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| US5928904A (en) | 1993-09-07 | 1999-07-27 | Smithkline Beecham Corporation | DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| US5631158A (en) | 1993-10-25 | 1997-05-20 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from non-native DNA |
| US5936065A (en) | 1993-12-06 | 1999-08-10 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| US5821231A (en) | 1993-12-06 | 1998-10-13 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using same |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US8715645B2 (en) | 1994-05-27 | 2014-05-06 | The Regents Of The University Of Colorado | Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same |
| US5622701A (en) | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
| US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| EP0873363B1 (en) | 1995-06-14 | 2010-10-06 | The Regents of The University of California | High affinity human antibodies to tumor antigens |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US6686350B1 (en) | 1996-07-25 | 2004-02-03 | Biogen, Inc. | Cell adhesion inhibitors |
| MY120425A (en) | 1996-07-26 | 2005-10-31 | Novartis Ag | Fusion polypeptides |
| US6423512B1 (en) | 1996-07-26 | 2002-07-23 | Novartis Ag | Fusion polypeptides |
| EP0981548A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF |
| US6191269B1 (en) | 1997-05-30 | 2001-02-20 | The Regents Of The University Of California | Selective induction of cell death by delivery of amino-terminal interleukin-1-α pro-piece polypeptide |
| DK0991619T3 (da) | 1997-06-23 | 2003-12-29 | Tanabe Seiyaku Co | Inhibitorer af alfa 4-beta 1-medieret celleadhæsion |
| US6455550B1 (en) | 1997-08-22 | 2002-09-24 | Hoffmann-La Roche Inc. | N-alkanoylphenylalanine derivatives |
| US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
| US6197794B1 (en) | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| US6171809B1 (en) | 1998-01-29 | 2001-01-09 | Packard Instrument Company | Method and compositions for detecting luciferase biological samples |
| ES2364266T3 (es) | 1998-04-03 | 2011-08-30 | Chugai Seiyaku Kabushiki Kaisha | Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado. |
| GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
| WO1999061421A1 (en) | 1998-05-28 | 1999-12-02 | Biogen, Inc. | A NOVEL VLA-4 INHIBITOR: oMePUPA-V |
| GB9812088D0 (en) | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
| US6685617B1 (en) | 1998-06-23 | 2004-02-03 | Pharmacia & Upjohn Company | Inhibitors of α4β1 mediated cell adhesion |
| US6355678B1 (en) | 1998-06-29 | 2002-03-12 | Parker Hughes Institute | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| CN101062419B (zh) | 1998-10-16 | 2016-06-29 | 生物基因Ma公司 | 干扰素-β-1a的聚合物缀合物及其使用 |
| US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
| JP3180906B2 (ja) | 1998-11-12 | 2001-07-03 | 日本電気株式会社 | 磁気抵抗効果型複合ヘッドの製造方法 |
| AU773388B2 (en) | 1999-02-18 | 2004-05-27 | F. Hoffmann-La Roche Ag | Thioamide derivatives |
| US8236159B2 (en) * | 1999-04-13 | 2012-08-07 | Applied Materials Inc. | Electrolytic process using cation permeable barrier |
| US6265572B1 (en) | 1999-04-20 | 2001-07-24 | Hoffmann-La Roche Inc. | Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agents |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US6579857B1 (en) * | 1999-06-11 | 2003-06-17 | Evanston Northwestern Healthcare Research Institute | Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors |
| US6756378B2 (en) | 1999-06-30 | 2004-06-29 | Pharmacopeia Drug Discovery, Inc. | VLA-4 inhibitor compounds |
| US7067313B1 (en) | 1999-07-14 | 2006-06-27 | D. Collen Research Foundation | Ligands for use in therapeutic compositions for the treatment of hemostasis disorders |
| US6365619B1 (en) | 1999-07-22 | 2002-04-02 | Novartis Ag | Treatment of arteriosclerosis |
| HUP0202469A3 (en) | 1999-08-13 | 2004-06-28 | Biogen Idec Ma Inc Cambridge | Cell adhesion inhibitor compound and pharmaceutical composition containing thereof |
| US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
| EP1094110A1 (en) | 1999-10-21 | 2001-04-25 | Leadd B.V. | Apoptosis inducing proteinaceous substance |
| JP4788939B2 (ja) | 1999-11-18 | 2011-10-05 | 味の素株式会社 | 新規フェニルアラニン誘導体 |
| US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
| US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| DE19962936A1 (de) | 1999-12-24 | 2001-06-28 | Bayer Ag | Neue beta-Aminosäureverbindungen als Integrinantagonisten |
| JP2003519697A (ja) | 1999-12-28 | 2003-06-24 | ファイザー・プロダクツ・インク | 炎症性疾患、自己免疫疾患および呼吸器疾患の処置に有用な非ペプチド系のｖｌａ−４依存性細胞結合阻害薬 |
| US7446174B2 (en) | 2001-03-02 | 2008-11-04 | Xencor, Inc. | Protein based TNF-α variants for the treatment of TNF-α related disorders |
| AU2001242743A1 (en) | 2000-03-23 | 2001-10-03 | Ajinomoto Co. Inc. | Novel phenylalanine derivative |
| JP2003530847A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050100991A1 (en) | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| DE60118362T2 (de) | 2000-05-19 | 2007-05-24 | The Center for Blood Research, Inc., Boston | VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN |
| GB0027328D0 (en) | 2000-06-23 | 2000-12-27 | Aventis Pharma Inc | Bioengineered vehicles for targeted nucleic acid delivery |
| US6787636B1 (en) | 2000-07-14 | 2004-09-07 | New Century Pharmaceuticals, Inc. | Modified serum albumin with reduced affinity for nickel and copper |
| US20040247565A1 (en) | 2000-07-19 | 2004-12-09 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US7015216B2 (en) | 2000-07-21 | 2006-03-21 | Elan Pharmaceuticals, Inc. | Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors |
| AU2001278986A1 (en) | 2000-07-21 | 2002-02-05 | Elan Pharmaceuticals, Inc. | 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors |
| RU2286340C2 (ru) | 2000-08-18 | 2006-10-27 | Адзиномото Ко., Инк. | Новые производные фенилаланина |
| KR20030036724A (ko) | 2000-09-14 | 2003-05-09 | 도레이 가부시끼가이샤 | 우레아 유도체 및 그것을 유효성분으로 하는 접착분자저해제 |
| ES2271071T3 (es) | 2000-09-25 | 2007-04-16 | Toray Industries, Inc. | Compuestos espiro e inhibidores de moleculas de adherencia que contienen dichos compuestos como ingrediente activo. |
| US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
| DK1370531T3 (da) | 2001-02-22 | 2007-06-25 | Celltech R&D Ltd | Phenylalaninenamidderivater der besidder en cyclobutengruppe, til anvendelse som integrininhibitorer |
| ES2180416B1 (es) | 2001-03-12 | 2004-06-01 | BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. | Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen. |
| KR100891272B1 (ko) | 2001-07-17 | 2009-04-06 | 리서치 디벨럽먼트 파운데이션 | 아폽토시스-촉진 단백질을 포함하는 치료제 |
| JP4164871B2 (ja) | 2001-07-26 | 2008-10-15 | 味の素株式会社 | 新規フェニルプロピオン酸誘導体 |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| JP4452899B2 (ja) | 2001-12-13 | 2010-04-21 | 味の素株式会社 | 新規フェニルアラニン誘導体 |
| KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2277889B1 (en) | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
| JP2005530482A (ja) | 2002-01-04 | 2005-10-13 | ゼンコー・インコーポレイテッド | ドミナントネガティブタンパク質およびそれらの用法 |
| CA2480039A1 (en) | 2002-03-22 | 2003-10-02 | Toray Industries, Inc. | Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| GB0216568D0 (en) | 2002-07-17 | 2002-08-28 | Celltech R&D Ltd | Chemical compounds |
| GB0216571D0 (en) | 2002-07-17 | 2002-08-28 | Celltech R&D Ltd | Chemical compounds |
| US7314613B2 (en) | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| US20040115204A1 (en) | 2002-12-11 | 2004-06-17 | Fanger Gary R. | Antibodies to treat cancer |
| WO2004082640A2 (en) | 2003-03-19 | 2004-09-30 | New Century Pharmaceuticals, Inc. | Human serum albumin conjugates with therapeutic compounds |
| US7446125B2 (en) | 2003-04-09 | 2008-11-04 | Universidad Del Pais Vasco | Derivatives of nitroproline compounds, processes of manufacture and uses in the treatment of integrin mediated disorders |
| WO2005035719A2 (en) | 2003-10-03 | 2005-04-21 | Board Of Control Of Michigan Technological University | Modified luciferase |
| US7638331B2 (en) | 2004-01-02 | 2009-12-29 | The Administration of the Tulane Rducation Fund | Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery |
| ES2403055T3 (es) | 2004-04-13 | 2013-05-13 | F. Hoffmann-La Roche Ag | Anticuerpos anti-P-selectina |
| CN1997382A (zh) | 2004-05-05 | 2007-07-11 | 梅里麦克制药股份有限公司 | 调节生物活性的双特异性结合剂 |
| MXPA06014031A (es) | 2004-06-01 | 2007-10-08 | Domantis Ltd | Anticuerpos de fusion biespecificos con vida media de serica mejorada. |
| TW200610754A (en) | 2004-06-14 | 2006-04-01 | Daiichi Seiyaku Co | Vla-4 inhibitor |
| US20060018859A1 (en) | 2004-07-16 | 2006-01-26 | Carter Daniel C | Modified human serum albumin with reduced or eliminated affinity to chemical or biological contaminants at Cys 34 |
| US7196112B2 (en) | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
| CN101072581A (zh) | 2004-10-05 | 2007-11-14 | 健泰科生物技术公司 | 具有减少的毒性的治疗剂 |
| KR20070107687A (ko) | 2004-12-31 | 2007-11-07 | 제넨테크, 인크. | Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도 |
| WO2006091209A2 (en) | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| US20070243163A1 (en) | 2006-02-17 | 2007-10-18 | Chih-Ping Liu | Respiratory tract delivery of interferon-tau |
| DK2615108T3 (en) | 2006-09-08 | 2017-01-30 | Ambrx Inc | Modified human plasma polypeptide or fc scaffolds and their applications |
| JP2010503396A (ja) * | 2006-09-14 | 2010-02-04 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合タンパク質 |
| US8580263B2 (en) | 2006-11-21 | 2013-11-12 | The Regents Of The University Of California | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
| US8343950B2 (en) * | 2006-12-15 | 2013-01-01 | Concert Pharmaceuticals, Inc. | Quinazoline derivatives and methods of treatment |
| MX2010011145A (es) | 2008-04-11 | 2011-04-11 | Merrimack Pharmaceuticals Inc | Enlazadores de la albumina de suero humana y conjugados de la misma. |
| ES2433424T3 (es) * | 2008-08-15 | 2013-12-11 | Merrimack Pharmaceuticals, Inc. | Métodos y sistemas para predecir respuesta de células frente a un agente terapéutico |
| WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| WO2011133668A2 (en) | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
| AU2011255238B2 (en) * | 2010-05-21 | 2015-06-04 | Silver Creek Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| ES2666856T3 (es) * | 2011-11-04 | 2018-05-08 | Novartis Ag | Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media |
| US9345766B2 (en) * | 2012-08-30 | 2016-05-24 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-ERBB3 agents |
-
2009
- 2009-10-14 WO PCT/US2009/060721 patent/WO2010059315A1/en not_active Ceased
- 2009-10-14 CN CN2009801545099A patent/CN102282168A/zh active Pending
- 2009-10-14 BR BRPI0921586A patent/BRPI0921586A2/pt not_active IP Right Cessation
- 2009-10-14 JP JP2011536365A patent/JP5677972B2/ja not_active Expired - Fee Related
- 2009-10-14 KR KR1020117014075A patent/KR20110112301A/ko not_active Ceased
- 2009-10-14 US US13/130,007 patent/US8927694B2/en not_active Expired - Fee Related
-
2010
- 2010-04-09 US US12/757,801 patent/US20110059076A1/en not_active Abandoned
-
2014
- 2014-12-24 US US14/582,719 patent/US20150191545A1/en not_active Abandoned
-
2016
- 2016-08-30 US US15/251,158 patent/US20170204192A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012509259A5 (OSRAM) | ||
| Gandullo-Sánchez et al. | HER3 in cancer: from the bench to the bedside | |
| JP2015534577A5 (OSRAM) | ||
| JP2021102648A (ja) | 抗ｆｏｌｒ１免疫複合体投与計画 | |
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| JP2018509182A5 (OSRAM) | ||
| JP2010531140A5 (OSRAM) | ||
| JP2009541492A5 (OSRAM) | ||
| JP2018525354A5 (OSRAM) | ||
| JP2024508894A (ja) | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 | |
| JP2020501531A5 (OSRAM) | ||
| JP2018516969A5 (OSRAM) | ||
| JP2018516966A5 (OSRAM) | ||
| CN117442719A (zh) | 用于治疗肺癌的抗pd-1抗体 | |
| JP2016502504A5 (OSRAM) | ||
| JP2015534578A5 (OSRAM) | ||
| JP2014502955A5 (OSRAM) | ||
| JP2024069254A (ja) | 神経障害及び疼痛のｅｇｆｒ標的治療 | |
| JP2010520290A5 (OSRAM) | ||
| JP2019524713A5 (OSRAM) | ||
| JP2011505371A5 (OSRAM) | ||
| CN118401259A (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| JPWO2021251459A5 (OSRAM) | ||
| JP7130243B2 (ja) | 二重特異性抗体を用いた抗体薬物複合体プラットホーム | |
| CN111278462A (zh) | 抗egfr抗体药物结合物(adc)和其用途 |